You are viewing an inactive listing

This listing is not currently available. You can either be notified when it becomes available or browse nearby active listings below.

Click here to view additional nearby listings or search by keyword.

Duluth, Minnesota 55805

  • Endometrial Cancer


RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known whether radiation therapy is more effective than observation only after sugery in treating endometrial cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to observation only in treating patients with stage I or stage II endometrial cancer who have undergone hysterectomy and oophorectomy.

Study summary:

OBJECTIVES: - Compare the overall survival in patients with intermediate-risk endometrial cancer treated with pelvic radiotherapy vs observation after laparoscopically-assisted vaginal hysterectomy or total abdominal hysterectomy and bilateral salpingo-oophorectomy. - Compare the time to locoregional recurrence (i.e., in the vaginal mucosa or elsewhere in the central pelvic area or lateral pelvic walls) in patients treated with these regimens. - Compare the duration of ultimate pelvic control and event-free survival in patients treated with these regimens. - Compare the toxic effects of these regimens in these patients. - Compare the quality of life of patients treated with these regimens. - Compare sexual health issues in patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified by center, tumor grade (1 vs 2 vs 3), surgical staging (yes vs no), and sexual health assessment (yes vs no). Patients undergo laparoscopic-assisted vaginal hysterectomy or total abdominal hysterectomy and bilateral salpingo-oophorectomy. After surgery, patients are randomized to 1 of 2 treatment arms. - Arm I: Patients undergo observation alone. - Arm II: Beginning within 12 weeks (preferably within 6-8 weeks) after surgery, patients undergo radiotherapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity. Protocol-defined brachytherapy is allowed. Quality of life is assessed at baseline; at 16-18 weeks after surgery (arm I) or 5 and 9 weeks after initiating radiotherapy (arm II); and then at 6, 12, 18, 24, 36, 48, and 60 months. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically proven adenocarcinoma or adenosquamous cell carcinoma of the endometrium - Intermediate-risk of recurrence after laparoscopically-assisted vaginal hysterectomy (with or without laparoscopic staging) or total abdominal hysterectomy and bilateral salpingo-oophorectomy - Postoperative pathologic stage IA/IB (grade 3), stage IC (grade 1-3), or stage IIA (all grades) - Patients with more than 50% myometrial invasion (grade 1 or 2) or less than 50% myometrial invasion (grade 3) but with positive peritoneal cytology also eligible - Patients whose sole criterion for increased risk is positive peritoneal cytology are not eligible - No pathologically involved lymph nodes if staging procedure performed - Stage I papillary serous or clear cell endometrial cancer allowed PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - ECOG 0-3 Life expectancy: - At least 3 years Hematopoietic: - WBC at least 2,000/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Not specified Renal: - Creatinine less than 2 times upper limit of normal - No serious renal disease that would preclude radiotherapy Cardiovascular: - No serious cardiovascular disease that would preclude radiotherapy Other: - No history of inflammatory bowel disease such as ulcerative colitis - No other malignancy within past 5 years except curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, colon cancer, or thyroid cancer - No psychiatric or addictive disorder that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Not specified Endocrine therapy: - No prior anticancer hormonal therapy - No concurrent progestogens Radiotherapy: - No prior pelvic irradiation - No prior or other concurrent vaginal intracavitary radiotherapy Surgery: - See Disease Characteristics Other: - No prior anticancer therapy - No other concurrent anticancer therapy



Primary Contact:

Study Chair
Himu R. Lukka, MD
Margaret and Charles Juravinski Cancer Centre

Backup Contact:


Location Contact:

Duluth, Minnesota 55805
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.